ADENOVIRUS TYPE 4 AND TYPE 7 VACCINE LIV

The Defense Logistics Agency has awarded TEVA PHARMACEUTICALS USA, INC. a firm fixed-price delivery order under the basic indefinite-delivery, indefinite-quantity contract SPE2DP-20-D-0002 for the procurement of 9 packages of Adenovirus Type 4 and Type 7 Vaccine, Live, identified by NSN 6505016420106 and NDC 51285-0138-50. The total contract value is $171,763.20 with a unit price of $19,084.80 per package, and the delivery is required to be completed by July 21, 2026, with FOB destination terms placing full transportation risk and responsibility on the contractor until receipt at the designated locations in Fort Detrick, MD, and San Diego, CA. The awardee is certified as a Women-Owned Small Business with a CAGE code of 3V8D7, and the vaccine is manufactured under CAGE code 0AZ22 with part number V24509A-20-07-CF-07. Payment terms are Net 30 days, with invoices required to be submitted electronically through WAWF in compliance with DFARS 252.232-7003, and the payment office code is SL4701. All shipments must be sent by the fastest traceable means, excluding parcel post, and must be properly marked with "SEE SCHEDULE" for Defense Finance and Accounting Service and BSMB Personnel, accompanied by the Transport Control Number W25MWY61940724 and the Requested Delivery Date of 203. The government retains the authority to inspect and accept the product at the destination, and while no specific MIL-STD packaging or preservation standards are explicitly cited, the nature of the live vaccine implies adherence to cold chain requirements. The contracting officer is Melissa Rios Thomas, with Hannibal Pajel listed as the receiving official for technical oversight. No options, modifications, or additional clauses beyond those referenced in the base contract are included, and the contract carries a zero quantity variance allowance. The acquisition is funded under accounting identifier 97X4930 5CBX 001 2620 S33189, and the NAICS code is